Tax withholding trims Sarepta (NASDAQ: SRPT) EVP's stock stake

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. executive Cristin Rothfuss, EVP and General Counsel, reported a routine tax-related share disposition. On March 11, 2026, the company withheld 974 shares of common stock at $17.03 per share to satisfy tax obligations from restricted stock units that vested on March 10, 2025.

After this withholding, Rothfuss directly holds 137,544 shares of Sarepta common stock, so the transaction represents only a small portion of her overall position and does not reflect an open-market sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rothfuss Cristin

(Last) (First) (Middle)

215 FIRST STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		F(1)		974	D	$17.03	137,544	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 10, 2025.

	/s/ Cristin L. Rothfuss	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Sarepta Therapeutics (SRPT) EVP Cristin Rothfuss’s latest Form 4 report?

The Form 4 shows 974 Sarepta shares withheld from EVP and General Counsel Cristin Rothfuss. The company used these shares to cover tax obligations tied to restricted stock units that vested on March 10, 2025, rather than an open-market sale.

Was the SRPT Form 4 transaction an open-market sale of Sarepta shares?

No, the Form 4 for Sarepta Therapeutics (SRPT) reports a tax-withholding disposition, not an open-market sale. Shares were withheld by the company to satisfy tax liabilities from vesting restricted stock units granted earlier, instead of being sold in the market.

How many Sarepta (SRPT) shares were withheld from Cristin Rothfuss for taxes?

The filing shows that 974 shares of Sarepta common stock were withheld at $17.03 per share. These shares were applied to cover Rothfuss’s tax withholding obligations related to the vesting of restricted stock units on March 10, 2025.

How many Sarepta (SRPT) shares does Cristin Rothfuss hold after this Form 4 event?

After the tax-withholding transaction, Cristin Rothfuss directly holds 137,544 shares of Sarepta common stock. This shows that the 974 shares withheld for taxes represent a small fraction of her total reported ownership position.

What caused the tax withholding reported in Sarepta (SRPT) EVP Cristin Rothfuss’s Form 4?

The tax withholding arose from the vesting of restricted stock units that were granted on March 10, 2025. When those RSUs vested, Sarepta withheld 974 shares from Cristin Rothfuss to meet the associated tax obligations.

What is the role of Cristin Rothfuss in Sarepta Therapeutics (SRPT) mentioned in the Form 4?

In the Form 4, Cristin Rothfuss is identified as Sarepta Therapeutics’ Executive Vice President and General Counsel. The reported transaction reflects a tax-related share withholding connected to her equity compensation, rather than discretionary buying or selling activity.